Physician profile
Robert L Staples
NPI 1881670446
$3,725.80
in general payments reported to CMS, 2019-2025
16 companies · $2,163 in 2025
The $2,163 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.11 · 2021: $21.90 · 2022: $179 · 2023: $194 · 2024: $1,076 · 2025: $2,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,080 · Travel and Lodging: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,079.99 |
| Travel and Lodging | $353.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,534.20 | 2024-2025 | |
| Abbvie INC. | $610.67 | 2022-2025 | Alphagan P, Lumigan |
| Bausch & Lomb Americas INC. | $243.02 | 2023-2025 | Vyzulta, Miebo, Prolensa |
| Alcon Vision LLC | $240.99 | 2022-2025 | Clareon, Argos, Hydrus Microstent |
| Dompe US, INC. | $208.26 | 2021-2025 | Oxervate |
| Rxsight INC | $176.59 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Ocular Therapeutix, INC. | $175.48 | 2025 | Dextenza |
| Apellis Pharmaceuticals, INC. | $125.00 | 2025 | Syfovre |
| Sight Sciences, INC. | $106.03 | 2025 | Omni Surgical System |
| Shire North American Group INC | $92.11 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $54.44 | 2023-2024 | Veritas Vision System, Tecnis Iol |
| Harrow Eye, LLC | $43.85 | 2023-2025 | Vevye |
| Oyster Point Pharma, INC. | $39.72 | 2023-2024 | Tyrvaya, Ryzumvi |
| Amgen INC. | $39.19 | 2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $20.98 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $15.27 | 2024 | Omidria |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Staples listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.